Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLTP | P55058 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31311238 | 0.92 | PLTP (0.51) | PLTPRORCDGAT1LCKPTGDR2 | |
| SCHEMBL31311335 | 0.85 | ALDH1A1 (0.48) | LCKMAPTSMN1; SMN2ABL1 | |
| SCHEMBL31311339 | 0.83 | PLTP (0.44) | PLTPLCKABL1 | |
| SCHEMBL31311210 | 0.82 | LCK (0.45) | LCKABL1 | |
| SCHEMBL31311187 | 0.80 | LCK (0.48) | LCKMAPTSMN1; SMN2ABL1 | |
| SCHEMBL31311348 | 0.78 | MPL (0.42) | RORCLCKMAPTSMN1; SMN2ABL1 | |
| SCHEMBL28889073 | 0.76 | GCK (0.46) | RORCLCKABL1 | |
| SCHEMBL2316445 | 0.76 | RORC (0.51) | PLTPRORCDGAT1MAPTSMN1; SMN2 | |
| SCHEMBL31311393 | 0.74 | PLTP (0.46) | PLTPRORCLCKPTGDR2 | |
| SCHEMBL31311372 | 0.73 | ADORA2A (0.50) | PLTPPTGDR2TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |